Summary: Sofosbuvir-Based and Elbasvir/Grazoprevir Treatment Failures
Recommended and alternative regimens listed by evidence level and alphabetically for:
Sofosbuvir-Based Treatment Failures, With or Without Compensated Cirrhosisa 
|
|
RECOMMENDED
|
DURATION
|
RATING 
|
|
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg)b
|
12 weeks
|
I, A
|
|
ALTERNATIVE
|
DURATION
|
RATING
|
|
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) except for NS3/4 protease inhibitor inclusive combination DAA regimen failuresc
-
Not recommended for genotype 3 infection with sofosbuvir/NS5A inhibitor experience.
|
16 weeks
|
I, A
|
a For decompensated cirrhosis, please refer to the appropriate section.
b Genotype 3: Add weight-based ribavirin if cirrhosis is present and there are no contraindications.
c This regimen is not recommended for patients with prior exposure to an NS5A inhibitor plus NS3/4 PI regimens (e.g., elbasvir/grazoprevir).
|
